Efficacy
gastro-esophageal junction carcinoma, Tumor, breast cancer, Tumors, esophageal carcinoma
COLORECTAL CANCER, TUMOR, BREAST CANCER, TUMORS, ESOPHAGEAL CARCINOMA, CHOLANGIOCARCINOMA
Overall, confirmed partial response (PR) was observed in two patients per investigator assessments, including one patient with FGFR1-mutant (p.A354V) esophageal carcinoma and one with FGFR2-mutant (p.F276C) CCA (Fig. Tumor swimmer plot for all patients. Clinical response was evaluated using Response Evaluation Criteria in Solid Tumors v1.1 by investigators. Abbreviations: CRC, colorectal cancer; GC/GEJC, gastric or gastro-esophageal junction carcinoma; CCA, cholangiocarcinoma; EC, esophageal carcinoma; BC, breast cancer